Holen Sie sich die Stockscreener-App
3.49
4.12%
-0.15
Handel nachbörslich:
3.49
Schlusskurs vom Vortag:
$3.64
Offen:
$3.62
24-Stunden-Volumen:
310.89K
Relative Volume:
0.89
Marktkapitalisierung:
$195.26M
Einnahmen:
$163.78M
Nettoeinkommen (Verlust:
$25.88M
KGV:
5.3692
EPS:
0.65
Netto-Cashflow:
$-28.66M
1W Leistung:
-1.13%
1M Leistung:
+12.94%
6M Leistung:
-47.52%
1J Leistung:
-60.39%
1-Tages-Spanne:
$3.48
$3.645
1-Wochen-Bereich:
$3.4644
$3.69
52-Wochen-Spanne:
$2.75
$9.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Firmenname
Voyager Therapeutics Inc
Sektor
Branche
Telefon
857-259-5340
Adresse
75 HAYDEN AVENUE, LEXINGTON, MA
Vergleichen Sie VYGR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.49 | 195.26M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-02 | Eingeleitet | Citigroup | Buy |
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-10-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-26 | Eingeleitet | Guggenheim | Buy |
| 2024-03-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-07 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | Eingeleitet | Truist | Buy |
| 2023-03-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Herabstufung | BTIG Research | Buy → Neutral |
| 2021-02-03 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-24 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-06 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-15 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-09-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-02-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-11-28 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2017-10-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-23 | Bestätigt | Stifel | Buy |
| 2017-10-12 | Eingeleitet | Raymond James | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-28 | Fortgesetzt | Stifel | Buy |
Alle ansehen
Voyager Therapeutics Inc Aktie (VYGR) Neueste Nachrichten
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer - Stock Titan
BlackRock, Inc. Reduces Stake in Voyager Therapeutics Inc - GuruFocus
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annua - GuruFocus
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting | VYGR Stock News - GuruFocus
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting - GlobeNewswire
Voyager Therapeutics Presents New Data on Tau Silencing Gene Therapy VY1706 and Anti-Amyloid Gene Therapy at ASGCT Annual Meeting - Nasdaq
Revolutionary Alzheimer's Gene Therapy Achieves 73% Tau Reduction: Voyager's Breakthrough Data Revealed - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
JPMorgan Chase & Co. Decreases Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Geode Capital Management LLC Grows Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance
Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising Pipeline Developments - GuruFocus
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Franklin Resources Inc. Reduces Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Vanguard Group Inc. Grows Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Wellington Management Group LLP Boosts Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
American Century Companies Inc. Has $696,000 Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics stock hits 52-week low at $2.81 - Investing.com
Voyager Therapeutics stock hits 52-week low at $2.81 By Investing.com - Investing.com Canada
Institutional investors may adopt severe steps after Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) latest 15% drop adds to a year losses - simplywall.st
7 Analysts Assess Voyager Therapeutics: What You Need To Know - Benzinga
Voyager Therapeutics chief medical officer sells $34,594 in stock By Investing.com - Investing.com India
Top Executives Unload Thousands of Voyager Therapeutics Shares! - TipRanks
Voyager Therapeutics chief medical officer sells $34,594 in stock - Investing.com
Voyager Therapeutics stock hits 52-week low at $3.54 By Investing.com - Investing.com Philippines
Voyager reveals promising Alzheimer’s therapy data By Investing.com - Investing.com South Africa
Voyager Therapeutics stock hits 52-week low at $3.54 - Investing.com
Voyager Therapeutics Presents Promising Tau-Targeting Gene Therapy And Antibody Data At AD/PD 2025 - Nasdaq
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 - The Manila Times
Voyager reveals promising Alzheimer’s therapy data - Investing.com
Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, - GlobeNewswire
Voyager Therapeutics at Virtual CNS Forum: Strategic Insights on Neurotherapeutics - Investing.com UK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc.VYGR - PR Newswire
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT) - The Globe and Mail
Canaccord Genuity Group Cuts Voyager Therapeutics (NASDAQ:VYGR) Price Target to $12.00 - Armenian Reporter
Voyager Therapeutics (NASDAQ:VYGR) Earns “Buy” Rating from HC Wainwright - Defense World
Voyager Therapeutics COO Robin Swartz sells $30,927 in stock - MSN
Cantor Fitzgerald Reaffirms “Overweight” Rating for Voyager Therapeutics (NASDAQ:VYGR) - Defense World
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates - MSN
H.C. Wainwright maintains $30 target on Voyager Therapeutics stock By Investing.com - Investing.com Canada
Voyager Therapeutics’ Earnings Call Highlights Promising Future - TipRanks
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analysts - Benzinga
Voyager Therapeutics stock hits 52-week low at $3.67 - Investing.com
Voyager Therapeutics stock hits 52-week low at $3.67 By Investing.com - Investing.com Australia
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript - Insider Monkey
Voyager Therapeutics price target lowered to $10 from $12 at Wells Fargo - TipRanks
Voyager Therapeutics Inc earnings missed by $0.22, revenue fell short of estimates - Investing.com
Earnings call transcript: Voyager Therapeutics Q4 2024 sees stock dip post-earnings - Investing.com Australia
Voyager Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Finanzdaten der Voyager Therapeutics Inc-Aktie (VYGR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):